These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25568664)

  • 1. STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML.
    Oancea C; Rüster B; Brill B; Roos J; Heinssmann M; Bug G; Mian AA; Guillen NA; Kornblau SM; Henschler R; Ruthardt M
    Genes Cancer; 2014 Nov; 5(11-12):378-92. PubMed ID: 25568664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
    Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M
    PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stem cells.
    Zheng X; Oancea C; Henschler R; Ruthardt M
    Int J Oncol; 2009 Jun; 34(6):1521-31. PubMed ID: 19424569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα.
    Steinert G; Oancea C; Roos J; Hagemeyer H; Maier T; Ruthardt M; Puccetti E
    PLoS One; 2011; 6(7):e22540. PubMed ID: 21811629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation.
    Oancea C; Rüster B; Henschler R; Puccetti E; Ruthardt M
    Leukemia; 2010 Nov; 24(11):1910-9. PubMed ID: 20827285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.
    Ageberg M; Drott K; Olofsson T; Gullberg U; Lindmark A
    Genes Chromosomes Cancer; 2008 Apr; 47(4):276-87. PubMed ID: 18181180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
    Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
    Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel variant translocation (1;9)(p22;q34) resulting in a DEK/NUP214 fusion gene in a patient with acute myeloid leukemia: A case report.
    Hao Q; Zhang Q; Li C; Wei S; Li Q; Song Y; Mi Y
    Oncol Lett; 2017 Dec; 14(6):7021-7024. PubMed ID: 29344131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
    Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).
    Logan GE; Mor-Vaknin N; Braunschweig T; Jost E; Schmidt PV; Markovitz DM; Mills KI; Kappes F; Percy MJ
    Blood Cells Mol Dis; 2015 Jan; 54(1):123-31. PubMed ID: 25128083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model.
    Qin H; Malek S; Cowell JK; Ren M
    Oncogene; 2016 Oct; 35(43):5686-5691. PubMed ID: 27065320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of leukemia-initiating cells in acute promyelocytic leukemia.
    Testa U; Lo-Coco F
    Stem Cell Investig; 2015; 2():8. PubMed ID: 27358876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell.
    Puccetti E; Ruthardt M
    Leukemia; 2004 Jul; 18(7):1169-75. PubMed ID: 15103387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NUP214 in Leukemia: It's More than Transport.
    Mendes A; Fahrenkrog B
    Cells; 2019 Jan; 8(1):. PubMed ID: 30669574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
    Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
    Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
    Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
    Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
    Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
    Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.
    Ommen HB; Touzart A; MacIntyre E; Kern W; Haferlach T; Haferlach C; Tobal K; Hokland P; Schnittger S
    Eur J Haematol; 2015 Nov; 95(5):436-41. PubMed ID: 25605311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.